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Abstract
Background—Cardiac myosin-binding protein C (cMyC) is a cardiac-restricted protein that is 
more abundant than cardiac troponins (cTn) and is released more rapidly following acute 
myocardial infarction (AMI). We evaluated cMyC as an adjunct or alternative to cTn in the early 
diagnosis of AMI. 
Methods—In 1954 unselected patients presenting to the emergency department with symptoms 
suggestive of AMI, concentrations of cMyC and high (hs) and standard (s) sensitivity cTn were 
measured at presentation. The final diagnosis of AMI was independently adjudicated using all 
available clinical and biochemical information without knowledge of cMyC. The prognostic 
endpoint was long-term mortality.
Results—Final diagnosis was AMI in 340 patients (17%). Concentrations of cMyC at 
presentation were significantly higher in those with vs. without AMI (median 237 ng/L vs. 13 
ng/L, p<0.001). Discriminatory power for AMI, as quantified by the area under the receiver-
operating characteristic curve was comparable for cMyC (AUC; 0.924), hs-cTnT (0.927) and hs-
cTnI (0.922) and superior to cTnI measured by a contemporary sensitivity assay (0.909). 
Combination of cMyC with hs-cTnT or s-cTnI (but not hs-cTnI) led to an increase in AUC to 
0.931 (p<0.0001) and 0.926 (p=0.003), respectively. Use of cMyC more accurately classified
patients with a single blood test into rule-out or rule in categories: Net Reclassification 
Improvement (NRI) +0.149 vs hs-cTnT, +0.235 vs hs-cTnI (p<0.001). In early presenters (chest 
pain <3h), the improvement in rule-in/rule-out classification with cMyC was larger compared 
with hs-cTnT (NRI +0.256) and hs-cTnI (NRI +0.308; both p<0.001). Comparing the C
statistics, cMyC was superior to hs-cTnI and s-cTnI (p<0.05 both) and similar to hs-cTnT at 
predicting death at 3 years.
Conclusions—cMyC at presentation provides discriminatory power comparable to hs-cTnT and 
hs-cTnI in the diagnosis of acute myocardial infarction, and may perform favorably in patients 
presenting early after symptom onset.  
Clinical Trial Registration—URL: www.clinicaltrials.gov Unique Identifier: NCT00470587 
Key Words: myocardial infarction; myocardial ischemia; myosin binding protein; biomarker; 
troponin; cMyC
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Clinical Perspective
What is new? 
? Cardiac myosin-binding protein C (cMyC) is a recently described novel biomarker of 
cardiac injury and in small “proof-of concept” studies its serum concentration rises and 
falls more rapidly than that of troponin T and I. 
? This is the first study to assess the diagnostic and prognostic value of cMyC in patients 
presenting with possible acute myocardial infarction (AMI). 
? A rule-in/rule-out pathway using the novel biomarker was designed to compare 
discriminative power in a clinical setting.
What are the clinical implications?
? Diagnostic accuracy of cMyC for AMI was similar to that of hs-cTnT and hs-cTnI in the 
entire cohort but superior for those with chest pain of less than 3 hours duration (early 
presenters) when compared to hs-cTnT. 
? cMyC has correctly triaged more patients to “rule-out” or “rule-in” groups than either hs-
cTnI or hs-cTnT leaving a much smaller proportion in the observation groups. This 
advantage may facilitate early discharge of low-risk patients. 
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Of the 130 million attendances to Emergency Departments (ED) in the United States each year, 
approximately 7 million (6%) are due to acute chest pain.1 The assessment and triage of such 
patients has become increasingly complex as now only a small proportion of those with acute 
myocardial infarction (AMI) have the diagnostic ECG change of ST-segment elevation.2
Consequently, the identification of patients with AMI has become almost totally dependent on 
the measurement in the systemic circulation of cardiac troponin I (cTnI) or cardiac troponin T 
(cTnT). These biomarkers are released slowly3 - to overcome this hurdle, the analytic 
performance of the cTn assays has been enhanced markedly to measure the lower concentrations 
achieved before the late peak.4 Hence, the best assays can reliably measure cTn concentrations 
below the 99th centile of the healthy population. These high-sensitivity (hs) assays are 
increasingly available and are the subject of national and international guidelines describing their 
use to achieve more rapid triage.5,6 In particular, the European guidelines recommend the use of 
assays for hs-cTnI and hs-cTnT to rapidly rule-in and rule-out AMI.  Algorithms using widely 
based decision limits based on concentrations well below the population defined 99th centile (for 
rule out) and above the 99th centile (for rule in) markedly improves the sensitivity of rule-out and
specificity of rule-in . However, many patients presenting with chest pain have cTn 
concentrations that place them between these decision limits; in an indeterminate observation 
zone. These patients require repeat testing and subsequent second or third rounds of triage based 
on rates of change of cTn concentration over time.6-8 European guidelines also do not support the 
use of rapid rule-out/rule-in pathways using hs-cTn in patients presenting ‘too early’ after chest 
pain onset – only after 3 hours is the rule-out threshold at the limit of detection guideline-
compliant.6 This introduces systemic delays in allocation of evidence-based treatments and 
prolongs stay in the pressured and precious environment of the ED.
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Originally discovered by Offer et al in 19739, the myosin-binding protein C family 
consists of three isoforms, specific for slow skeletal, fast skeletal and cardiac muscle – the latter 
being exclusively expressed in the heart from neonatal throughout human development.10,11
Amongst others12-15, we have identified cardiac myosin-binding protein C (cMyC, see figure 1) 
as a new candidate biomarker of cardiac injury.16 In common with cTnT and cTnI, cMyC 
expression is restricted to the heart but it is more abundant.17 Moreover, cMyC rises more rapidly 
in the systemic circulation than hs-TnT after timed, iatrogenic AMI16, perhaps as a result of its 
higher myocardial concentration.18 Using a recently developed high-sensitivity assay for 
cMyC19, a pilot study in 26 patients presenting early with AMI suggested that cMyC may rise 
more rapidly than hs-cTnI.20
 The purpose of the current study is to compare the novel biomarker cMyC (measured on 
a research platform) against the most accurate currently available biochemical signals, hs-cTnI 
and hs-cTnT, for the early detection of AMI. 
Methods
Study design and population
Advantageous Predictors of Acute Coronary Syndrome Evaluation (APACE) is an ongoing 
international multicenter diagnostic study (nine study centers in Switzerland, Spain, Poland, the 
Czech republic, and Italy) designed to advance the early diagnosis of AMI.4,21-23 All patients 
older than 18 years presenting to the ED with acute chest discomfort possibly indicating AMI 
were eligible for recruitment if the onset of, or peak chest pain symptoms, were within the 
preceding 12 hours. Enrolment was independent of renal function, while patients with terminal 
kidney failure on chronic dialysis were excluded. For this analysis, the following patients were 
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excluded (figure S1): patients presenting with ST-segment elevation myocardial infarction; 
patients with missing levels of cMyC at presentation; patients in whom the final diagnosis 
remained unclear after adjudication and at least one hs-cTnT level was elevated. The latter group 
comprises of patients triaged and discharged following a negative gold-standard test at the time 
of enrolment (on a conventional cTn assay), who were later found to have an elevated hs-cTn 
result (comparison see table S1). A proportion of patients had no levels of cMyC measured at 
presentation due to insufficient sample volume. Demographics of the patients excluded due to 
missing cMyC values, compared to those of the test cohort, appear in the supplement (table S2). 
The protocol for routine clinical assessment is also described in the supplement. To obtain 
follow-up data, patients were contacted 3, 12, 24 and 36 months after discharge via telephone, 
email or letter. Additionally, information regarding death during follow-up was obtained from 
the patient’s hospital notes, the family physician’s records and the national registry on mortality. 
The study was carried out according to the principles of the Declaration of Helsinki and 
approved by the local ethics committees. Written informed consent was obtained from all 
patients. TK, RT and CM had full access to all the data in the study and take responsibility for its 
integrity and the data analysis. The authors designed the study, gathered, and analyzed the data 
according to the STARD guidelines for studies of diagnostic accuracy (table S3), vouch for the 
data and analysis, wrote the paper, and decided to publish.
Adjudicated final diagnosis
Adjudication of the final diagnosis was performed centrally according to the universal definition 
of MI, incorporating levels of hs-cTnT as the adjudicating biomarker.24 It was based on extensive 
patient documentation derived from two sets of data: First, all clinical data derived from routine 
clinical investigations including all available medical records - patient history, physical 
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examination, results of laboratory testing including serial local (h)s-cTn, radiologic testing, ECG, 
echocardiography, cardiac exercise stress test, lesion severity and morphology at coronary 
angiography - pertaining to the patient from the time of ED presentation to 90-day follow up. 
Second, study-specific assessment was collected, including 34 chest pain characteristics and 
serial hs-cTnT measurements in order to take advantage of the higher sensitivity and higher 
overall diagnostic accuracy offered by the more sensitive assays, as previously published.4,21 In 
situations of disagreement about the diagnosis, cases were reviewed and adjudicated in 
conjunction with a third cardiologist. In brief, AMI was diagnosed when there was evidence of 
myocardial necrosis in association with a clinical setting consistent with myocardial ischemia. 
Myocardial necrosis was diagnosed by at least one (h)s-cTn value above the 99th percentile 
together with a significant rise and/or fall.25-27 All other patients were classified into the 
categories of unstable angina (UA), cardiac but non-coronary disease (e.g. tachyarrhythmias, 
perimyocarditis), non-cardiac chest pain and symptoms of unknown origin. 
Measurement of cMyC, hs-cTnI, hs-cTnT, and s-cTnI
Blood samples for determination of cMyC, hs-cTnI, hs-cTnT, and s-cTnI were collected into 
heparin plasma and serum tubes at presentation to the ED and serially thereafter (at time points 1 
h, 2 h, 3 h and 6 h). Serial sampling was discontinued when a diagnosis of AMI was certain and 
treatment required patient transfer to the coronary care unit or catheter laboratory. After 
centrifugation, samples were frozen at -80ºC until they were assayed in a blinded fashion in a 
dedicated core laboratory. cMyC was measured using the previously established high-sensitivity 
assay on the Erenna platform that was performed by Millipore Sigma (Hayward, California).19
The assay has a Limit of Detection (LoD) of 0.4 ng/L and a lower limit of quantification (LoQ)
of 1.2 ng/L. The 99th percentile cut-off point determined previously (in patients without 
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obstructive coronary artery disease on invasive angiography) is 87 ng/L.19 Details of the assays 
used for hs-cTnI, hs-cTnT, and s-cTnI are described in the supplement. 
Early guideline-based triage and Net Reclassification Improvement
The European  Society of Cardiology (ESC) has published a rapid rule-in/rule-out pathway in  
the 2015 NSTEMI guidelines using hs-cTn at 0h and 1h to risk-stratify patients into ‘rule-out’, 
‘observe’ and ‘rule-in’ categories.6 Such categorization did not drive clinical decisions in this 
cohort, but it was used to compare the potential clinical utilities of cMyC and hs-cTn as triage 
tools. For this purpose, we have compared the categorical discrimination of hs-cTnT, hs-cTnI 
and cMyC at presentation only (without subsequent delta measurements). In brief, the ESC 
pathway classifies patients – based on the presentation sample at 0h – into ‘rule-out’ with a hs-
cTnT level <5 ng/L; hs-cTnI <2 ng/L; into ‘rule-??????????????????????????????????6 The ESC 
advocates the use of the pathway only in ???????????????????????????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????????????
alone.
 For cMyC we separated the cohort into derivation and validation cohorts (a randomized 
3:7 split, for comparison see table S4); the ‘rule-out’ threshold was derived from a pre-defined 
????????????????????????????-in’ from a pre-defined specificity >95% for the gold-standard 
diagnosis of AMI. This resulted in a ‘rule-out’ threshold ??????????????????????-in’ threshold of 
>120 ng/L for cMyC (figure S2). These thresholds were then used in the validation cohorts to 
compare cMyC against both hs-cTnT and hs-cTnI. NRI operates as follows: each patient is first 
assigned a classification (‘rule-out’, ‘observe’ or ‘rule-in’) based on cut-off values of hs-cTnI/T 
in the presentation blood sample (the initial model). The same cohort is then reclassified to the 
same three groups based on the cMyC cut-off values (the new model). This reclassification may 
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correctly or incorrectly reallocate a patient, e.g. a patient who went on to be diagnosed with an 
AMI may be correctly reclassified from ‘observe’ to ‘rule-in’, or incorrectly reclassified from 
‘observe’ to ‘rule-out’. The ‘NRI’ analysis defines separate categorical NRI values for those 
patients who were ultimately diagnosed with AMI (quoted as NRIAMI) and those who were not 
(NRInoAMI) – range -1 to +1; ‘Dimensionless NRI’ reflects the unweighted, net-movement of all 
patients regardless of final diagnosis (range -2 to +2). NRIAMI is positive if there is a net 
movement of patients with adjudicated AMI into higher-risk classifications using cMyC (the new 
model). NRInoAMI is positive there is a net movement of patients without an adjudicated diagnosis 
of AMI into lower-risk classifications using cMyC (the new model).28 NRI calculations were 
performed for the validation cohort, early presenters (<3 hours since onset of chest pain; ESC 
guideline not applicable???????????????????????????????????????????; ESC guideline applicable);
tables are presented in full where appropriate. 
Statistical analysis
All data are expressed as medians [1st quartile, 3rd quartile] or means (standard deviation) for 
continuous variables (compared with the Mann-Whitney-U test or student's t-test), and for 
categorical variables as numbers and percentages (compared with Pearson chi-square). 
Hypothesis testing was two-tailed, and p values <0.05 were considered statistically significant. 
No adjustment for multiple comparisons was performed.  
Discrimination power was quantified by the area under the receiver-operating 
characteristics curve (AUC) for each biomarker with all cases available, using 1,000 stratified 
bootstrap replicates to calculate Confidence intervals (CI). Logistic regression was used to 
combine cMyC levels with hs-cTnT, hs-cTnI or s-cTnI values for the assessment of an 
incremental value using two biomarkers at presentation. Sub-group analysis was performed for 
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patients presenting early, defined as chest pain onset within 3 hours of presentation to the 
Emergency Department. This is a particular limitation of the published ESC guidance on the use 
of hs-cTn for risk-stratification, as the rapid rule-out/rule-in algorithms are only applicable to 
patients with chest pain onset >3 hours. 
Predictive value of the biomarkers during follow-up was assessed two-fold: We 
calculated 1) Harrell’s C statistic for each biomarker at presentation for endpoints AMI, death or 
the composite of AMI and all-cause mortality during follow-up (excluding the index event) – a
higher C index indicates a higher probability of an event occurring during follow-up with higher 
biomarker values29; and 2) Kaplan-Meier survival curves. Cox regression analysis was 
performed as follows: All available biomarker levels were divided into 1) quintiles and 2) groups 
according to ‘rule-out’, ‘observe’ and ‘rule-in’ classification. Unadjusted Cox proportional 
hazard regression models were fitted for 30-day and 3-year follow-up for each group with the 
lowest quintile (or risk group, respectively) normalized to a hazard ratio of 1 and assessed using 
the likelihood-ratio test. Cox coefficients and thus hazard ratios were not calculated if the lowest 
risk group did not suffer any events, which would invalidate the regression model. NRI statistics 
were calculated as categorical values.28,30 The Integrated Discrimination Improvement (IDI) 
values quoted reflect a category-free (positive or negative) change in model-performance. 
Confidence intervals for cut-off thresholds, NRI and IDI statistics were derived using 1,000 
bootstrap replicates. All statistical analyses were performed using R, version 3.3.0 GUI 1.68 
(The R Foundation for Statistical Computing), including packages ggplot2, R Markdown, 
RStudio, PredictAbel, survival, Hmisc, compareC and ROCR. 
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Results
Baseline characteristics
A total of 1954 unselected patients eligible for this analysis were enrolled (Figure S1). Median 
age was 62 years, 31% were women, and 36% had a prior history of coronary artery disease 
(table 1). Overall, 1469 patients (75%) had no significant electrocardiographic abnormalities at 
presentation to the ED. Median time since onset of chest pain was 5 hours [IQR 3, 12], with a 
median of 3 hours [IQR 2, 7] since peak chest pain severity. 
The adjudicated final diagnosis was AMI in 340 (17%) patients, unstable angina in 10%, 
symptoms of cardiac origin other than coronary artery disease in 14%, non-cardiac symptoms in 
54% and symptoms of unknown origin in 5%. 
 Median follow-up for the entire cohort was 772 days [IQR 731, 907]; of those not 
sustaining any events in the monitoring period (AMI or death), the median follow-up was 792 
days [IQR 738, 923]. A total of n=165 (8%) patients died during 3-year follow-up. 1903 patients 
(97%) exceeded 90 days of follow-up; of those who did not (n=51, 3%), 27 (1%) sustained a 
cardiovascular death.
Distribution of biomarker concentrations
As shown in figure 2, cMyC levels were significantly higher in patients with AMI (n=340) 
compared to patients with other diagnoses (AMI, median 237 ng/L [IQR 71, 876 ng/L; unstable 
angina, median 21 ng/L [IQR 13, 43 ng/L]; cardiac symptoms of origin other than coronary 
artery disease, median 33 ng/L [IQR 12, 96 ng/L]; non-cardiac symptoms, median 10 ng/L [IQR 
6, 19 ng/L]; symptoms of unknown origin, median 11 ng/L [IQR 7, 16 ng/L]; p <0.001 for all 
comparisons with AMI patients). Similarly, blood concentrations of hs-cTnT, hs-cTnI, and s-
cTnI were significantly higher in AMI as compared to other final diagnoses (median biomarker 
 by guest on O
ctober 9, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.117.028084
12
concentrations displayed in tables S5+S6). Overall, blood concentrations of cMyC in relation to
LoD were higher than those of hs-cTn in all diagnostic categories (Table S5). Non-cardiac 
sources of cMyC variation were previously investigated in an ambulatory cohort19; results of 
comparison within the groups with AMI and non-cardiac symptoms have been displayed in 
tables S7+S8. 
Discrimination power
In blood drawn at presentation, the discrimination  of cMyC for AMI, as quantified by the AUC, 
was 0.924 (95% confidence interval [CI], 0.910-0.939), compared to the AUCs for hs-cTnT 
0.927 (95% CI, 0.913-0.941; p=0.573 for direct comparison); hs-cTnI 0.922 (95% CI, 0.908-
0.936; p=0.993 for direct comparison) and s-cTnI 0.909 (95% CI, 0.889-0.928; p=0.024 for 
direct comparison, table 2, figure 3). 
Early presenters
In patients presenting within 3 hours of symptom onset (n=694, with AMI adjudicated in 16%) 
the AUC for cMyC was 0.915 (95% CI, 0.887-0.941), compared to the AUCs for hs-cTnT 0.892
(95% CI, 0.857-0.922; p=0.022); hs-cTnI 0.909 (95% CI, 0.879-0.935; p=0.539) and s-cTnI 
0.892 (95% CI, 0.859-0.925; p=0.060) (table 2).  
Combination of cMyC with cTn 
AUC for the combination of cMyC with hs-cTnT was 0.935 (95% CI, 0.921-0.948; p=0.002 for 
comparison with hs-cTnT alone), cMyC with hs-cTnI 0.929 (95% CI, 0.913-0.943; p=0.093 for 
comparison with hs-cTnI alone) and cMyC with s-cTnI 0.928 (95% CI, 0.909-0.943; p<0.001 for 
comparison with s-cTnI alone) (table 2, figure S3).
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Classification function of cut-off values for risk groups 
Sensitivity, specificity, negative and positive predictive values were calculated for derivation 
(tables S9, S10) and validation cohorts based on cut-offs published in the 2015 ESC guideline6:
in the validation cohort (n=1,368, 233 events), hs-cTnT has a sensitivity of 99.6% (95% CI, 
98.5-100%) and NPV of 99.7% (95% CI, 99-100%) at the rule-out threshold of 5 ng/L, 
specificity of 97.1% (95% CI, 96.1-98%) and PPV 80.1% (95% CI, 73.2-86.2%) at the rule-in 
threshold (52 ng/L); hs-cTnI has a sensitivity of 100% (95% CI, 100-100%) and NPV of 100% 
(95% CI, 100-100%) at 2 ng/L, specificity of 94.5% (95% CI, 93-95.8%) and PPV 70.4% (95% 
CI, 63.6-76.5%) for rule-in – table 3. After obtaining clinically meaningful cut-off thresholds in 
the internal derivation cohort (tables S9, S10; figure S2; ?????????????????????????????????????????
>95%), these were tested in the validation cohort: at a threshold of 10 ng/L for rule-out, cMyC
achieves a sensitivity of 99.6% (95% CI, 98.6-100%) and NPV of 99.8% (95% CI, 99.3-100%). 
At 120 ng/L for the rule-in threshold, cMyC achieves a specificity of 94.7% (95% CI, 93.3-
95.9%) and PPV of 71% (95% CI, 64.9-77.2%); all data in table 3. 
???????????????????????????????????????????????????????????????????????????????????????????
chest pain) is presented in tables S11 and S12. In short, in early presenters cMyC demonstrates 
higher sensitivity than hs-cTnT (100% vs 98.8%) and greater specificity (46.4% vs 33.3%) at the 
rule-out threshold (10 ng/L). Sensitivity is similar for cMyC and hs-cTnI, however again with 
greater specificity for cMyC (47.1% vs 23.2%). In the group of late presenters, cMyC yields 
higher specificity (37.3% vs hs-cTnT 28.4%, 38.1% vs hs-cTnI 15.9%) at the rule-out threshold 
with otherwise comparable sensitivity. Specificity for adjudicated diagnosis of AMI was 
individually assessed at the 99th centile in table S13. 
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Risk group reclassification
The distribution of patients in risk groups ‘rule-out’, ‘observe’ and ‘rule-in’ based on the initial 
blood test (either hs-cTnT, hs-cTnI or cMyC) is displayed in figure 4 (validation cohort, n=1368, 
AMI in 17%). cMyC classified 443 patients (32.4%) safely as rule-out, compared to 348 (25.4%)
with hs-cTnT and 206 (15.1%) with hs-cTnI – predominantly by reducing the size of the 
observation group.
 In the validation cohort (table 3), cMyC at presentation was superior to hs-cTnT with 
NRI +0.149 (NRInoAMI +0.081, NRIAMI +0.068; p <0.001), and to hs-cTnI with NRI +23.5
(NRInoAMI +0.226, NRIAMI +0.009; p <0.001). In the cohort of early presenters (<3 hours of chest 
pain), cMyC was superior to hs-cTnT with NRI +0.256 (NRInoAMI +0.256, NRIAMI +0.128; p 
<0.001), and to hs-cTnI with NRI +0.308 (NRInoAMI +0.257, NRIAMI +0.051; p <0.001); table
S11????????????????????????????????????????????????????????????????????????????????????-cTnT 
with NRI +0.133 (NRInoAMI +0.084, NRIAMI +0.049; p <0.001), and to hs-cTnI with NRI +0.227 
(NRInoAMI +0.240, NRIAMI -0.012; p <0.001); table S12. 
Prognostic performance of cMyC
As quantified by Harrell’s C statistic calculated from the presentation sample (table S14), cMyC 
matched the performance of hs-cTnT in predicting AMI (excluding index event), death and the 
composite endpoint within a 3-year follow-up. Compared to hs-cTnI, there was a statistically 
different but numerically small improvement in predicting death and the composite endpoint at 3 
years: cMyC C index 0.767 vs hs-cTnI 0.732 (p=0.001) and 0.746 vs 0.722 (p=0.008), 
respectively; AMI was comparable. cMyC was significantly better at predicting AMI, death or 
the composite endpoint when compared to cTnI. 
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 For the calculation of cumulative hazard ratios (HR) for all-cause mortality using a Cox 
regression model, each biomarker was separated into quintiles. HR for hs-cTnT at three year 
follow-up was 2.3 (95% CI, 0.6-9.0) in the second quintile, 7.7 (95% CI, 2.3-25.8) in the third, 
17.7 (95% CI, 5.5-57.1) in the fourth and 33.6 (95% CI, 10.6-106.3) in the fifth quintile - p <0.05 
for all except 2nd quintile. The HR for hs-cTnI was 6.6 (95% CI, 1.5-29.2), 11.3 (95% CI, 2.7-
48.3), 25.1 (95% CI, 6.1-103.3) and 39.7 (95% CI, 9.7-161.8), respectively - p <0.05 for all 
quintiles. The HR for cMyC was 2.6 (95% CI, 0.7-10.0), 7.8 (95% CI, 2.3-25.9), 17.2 (95% CI, 
5.4-55.0) and 29.4 (95% CI, 9.3-93.2) – p <0.05 for all except 2nd quintile. Survival curves for 
cMyC and hs-cTn assays are displayed in figures S4A-C for three-year and 30-day follow-up. 
Discussion
To our knowledge, cMyC is the first cardiac-restricted protein to be analyzed as a diagnostic test 
for AMI since cTn. In this diagnostic multicenter study we compared its diagnostic performance 
to cTnI and cTnT, measured using the leading high-sensitivity assays recommended in current 
practice guidelines6, in a well-characterized and large cohort of patients presenting with 
symptoms suggestive of AMI. Discrimination for MI with cMyC was similar to that of hs-cTnT 
and hs-cTnI and superior to s-cTnI. In patients presenting within 3 hours of chest pain onset, 
cMyC was superior to hs-cTnT, despite the latter’s use as the adjudicating biomarker. Using cut-
offs for cMyC calibrated against those recommended in guidelines6, cMyC correctly and safely 
rules-out and rules-in AMI in a greater proportion of patients than either hs-cTnT or hs-cTnI. 
These findings indicate that cMyC may be better able to triage patients presenting to the ED with 
suspected AMI.
 cTnT and cTnI have transformed the management of patients with suspected AMI and 
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their importance is enshrined in the Universal Definition of Myocardial Infarction.31
Consequently, AMI events are identified/adjudicated based on a significant rise (and/or fall) in 
cTnT/I blood concentration. This definition has harmonized clinical care and clinical research, 
but also introduced an inherent bias in favor of cTnT/I versus novel diagnostic biomarkers in 
studies such as ours. cMyC is not part of the troponin complex and has a distinct location within 
the cardiac sarcomere (figure 1). For these reasons, our findings regarding the performance of 
cMyC against the hs-cTnT and hs-cTnI “gold-standard”, are notable. Since cMyC was not 
measured through the patients’ journey, it is a matter of speculation if the outcome would have 
been different with cMyC as the adjudicating biomarker.
 After iatrogenic or spontaneous AMI cMyC appears more rapidly in the systemic 
circulation than either hs-cTnT or hs-cTnI.16,20 This is probably due to a combination of cMyC’s 
greater myocardial abundance, distinct sarcomeric location and loose association with myosin 
and actin.16 This biological distinctiveness of cMyC likely underpins the diagnostic advantage 
we observed over hs-cTnT/I in patients presenting within 3 hours of symptom onset. Moreover, 
the more rapid appearance of cMyC in the systemic circulation after cardiac injury is also likely 
to explain the net reclassification improvement over both hs-cTnT and hs-cTnI. 
There are no large prospective clinical trials comparing the effect of different biomarkers 
of cardiac necrosis on clinical outcome. Nonetheless it is interesting to speculate what effect the 
improved classification of events by cMyC could have in clinical practice. The current guidelines 
identify three risk groups, where only hs-cTn concentrations at the limit of detection or 
significantly above the 99th centile clearly triages patients towards rule-out or rule-in of AMI, 
respectively.6 This leaves a significant proportion of patients within the ‘observe’ zone of clinical 
uncertainty requiring repeat cTn measurement and further investigation.32 In the current study, of 
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the patients who ultimately did not have AMI, the proportion in the observe-zone after the first 
measurement at presentation was 55.2% using hs-cTnT, 63.2% using hs-cTnI and 46.1% using 
cMyC. It is expected that the greater diagnostic certainty afforded on a single presentation blood 
draw by cMyC may reduce median time to discharge and costs of investigations.  
As yet, near-patient, point-of-care devices have not been able to rule-out AMI since they 
have struggled to achieve the required analytic sensitivity to measure low concentrations of cTnT 
or cTnI. In addition, the development of reliable large-platform based hs-cTn assays has proved 
more challenging than expected. Until now, only two manufacturers have overcome the 
difficulties of developing and introducing hs-cTn assays into clinical practice6, of which one had 
major quality issues initially.33-35 These uncertainties and concerns have led to delays in the 
approval of these assays for clinical care in the United States.36 The Food and Drug 
Administration has only recently ratified the use of the 5th generation hs-cTnT assay.37 Since 
cMyC is more abundant and rises more rapidly, migration to a point-of-care format may be less 
challenging. Risk prediction appears grossly similar when comparing hs-cTn and cMyC and 
could therefore be performed on either. Notably, a cMyC level below 10 ng/L (the threshold 
resembling 25-times the Limit of Detection) offers both very high NPV and 30-day mortality 
rates approaching zero.
 There are a number of limitations to our study. First, the diagnostic cut-offs for cMyC
require external validation: Despite its size, a single cohort cannot entirely safeguard against 
calibration-issues and is inherently subject to potential, institutional bias. We have attempted to 
mitigate these risks by employing both randomization and bootstrapping, but in an ideal scenario 
the findings were validated in an independent cohort. Second, the analyses within this 
manuscript are confined to the concentration of necrosis biomarker on first blood draw. We have 
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not analyzed the effect on the grey zone of repeat blood draws after set intervals. This is an area 
of active research for which there is no consensus regarding resampling interval, magnitude of 
concentration change, use of absolute or relative change in concentration or effect of assay 
vendor.4,5,21,38-40 Third, as a prospective diagnostic study, we cannot exactly quantify the clinical 
benefit associated with the use of cMyC as an alternative or addition to hs-cTn – further cluster-
randomized studies will be required to address this issue. Fourth, we cannot comment on the 
accuracy of cMyC among patients with terminal kidney failure on renal replacement therapy or 
ST elevation myocardial infarction, since such patients were excluded from this study. Currently, 
biomarkers have no role in the assessment of patients with STEMI and hence this group was not 
analyzed. Fifth, of 3029 patients recruited, 875 had no baseline cMyC measured; however, a 
comparison between the analyzed cohort and the excluded patient sample has not demonstrated 
substantial differences in baseline characteristics (suppl. table 3S). Sixth, in patients with low 
levels of cMyC (e.g. the non-cardiac chest pain group), we have observed a significant difference
in biomarker values dependent on certain underlying conditions (such as prior coronary artery 
disease; suppl. tables S7-8); however, this effect is muted in patients with AMI, and indeed did 
not negatively influence specificity. Finally, cMyC was measured using a research platform,
whilst hs-cTnI and hs-cTnT were measured using widely available clinical laboratory analyzers.
The sandwich immunoassay is comparable to the setup used to test for hs-cTn, but cMyC is not 
yet available on a random-access laboratory analyzer for routine clinical use.
 In summary, cMyC is a promising new biomarker of myocardial necrosis with overall 
discriminatory power comparable with the leading troponin assays in AMI diagnosis. A potential 
advantage of cMyC is its ability to more effectively rule-out AMI at presentation, particularly 
among those presenting early after symptom onset.  
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Table 1. Demographics
Demographics All patients(n = 1954) 
AMI
(n = 340) 
Other 
diagnoses 
(n = 1614)
p value*
Age, years 62 ± 16 69 ± 13 60 ± 16 <0.001
Male 1341 (69) 256 (75) 1085 (67) 0.004
Risk factors
Hypertension 1247 (64) 269 (79) 978 (61) <0.001
Hyperlipidaemia 992 (51) 227 (67) 765 (47) <0.001
Diabetes mellitus 369 (19) 92 (27) 256 (16) <0.001
Current smoking 500 (25) 90 (27) 386 (24) 0.345
History of smoking 718 (38) 141 (42) 577 (36) 0.051
History
Coronary artery disease 710 (36) 174 (51) 536 (33) <0.001
Previous myocardial infarction 474 (24) 118 (35) 356 (22) <0.001
Previous revascularisation (CABG or PCI) 553 (28) 127 (37) 426 (26) <0.001
Peripheral artery disease 119 (6) 43 (13) 76 (5) <0.001
Previous stroke 100 (5) 23 (7) 77 (5) 0.167
Vital status
Heart rate, beats/min 79 ± 20 81 ± 20 79 ± 20 0.092
Systolic blood pressure, mm Hg 144 ± 24 145 ± 27 143 ± 24 0.421
Diastolic blood pressure, mm Hg 82 ± 15 81 ± 17 82 ± 15 0.299
Electrocardiographic findings
ST-segment depression 193 (10) 93 (28) 100 (6) <0.001
T-wave inversion 260 (13) 82 (24) 178 (11) <0.001
No significant electrocardiographic abnormalities 1469 (75) 161 (49) 1308 (83) <0.001
Laboratory assessment
Estimated glomerular filtration rate, ml/min/1.73m2† 84 ± 26 74 ± 26 86 ± 25 <0.001
Presentation time
Time since chest pain onset, hours 5 [3, 12] 5 [3, 12] 5 [3, 12] 0.898
Time since chest pain peak, hours 3 [2, 7] 3 [2, 7] 4 [2, 7] 0.408
Legend: * p values for comparison AMI group versus all other diagnoses; data are expressed as medians 
[1st quartile, 3rd quartile] or means ± standard deviation, for categorical variables as numbers 
(percentages); AMI = Acute Myocardial Infarction; IQR = Interquartile Range; CABG = Coronary Artery 
Bypass Graft; PCI = Percutaneous Coronary Intervention; † glomerular filtration rate was estimated using 
the Modification of Diet in Renal Disease (MDRD) formula
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Table 2. Area under the Receiver-Operating Characteristics Curve – Comparisons between 
biomarkers
All patients - comparison Area Under the Curve (95% Confidence Interval) p value* n 
cMyC vs hs-cTnT 0.924 (0.910-0.939) vs 0.927 (0.913-0.941) 0.573 1554 controls, 322 AMI
cMyC vs hs-cTnI 0.923 (0.908-0.937) vs 0.922 (0.908-0.936) 0.993 1537 controls, 320 AMI
cMyC vs s-cTnI 0.924 (0.906-0.938) vs 0.909 (0.889-0.928) 0.024 1463 controls, 311 AMI
????????????????????????????????????????????????????- comparison
cMyC vs hs-cTnT 0.915 (0.887-0.941) vs 0.892 (0.857-0.922) 0.022 562 controls, 104 AMI
cMyC vs hs-cTnI 0.915 (0.889-0.939) vs 0.909 (0.879-0.935) 0.539 554 controls, 102 AMI
cMyC vs s-cTnI 0.914 (0.888-0.939) vs 0.892 (0.859-0.925) 0.060 529 controls, 103 AMI
All patients - Combination cMyC with… p value† n
hs-cTnT 0.935 (0.921-0.948) 0.002 1548 controls, 322 AMI
hs-cTnI 0.929 (0.913-0.943) 0.093 1537 controls, 320 AMI
s-cTnI 0.928 (0.909-0.943) <0.001 1463 controls, 311 AMI
Legend: *p value for direct comparison between biomarkers; †p value for direct comparison between 
AUC for combination (cMyC with cTn) and respective cTn on its own; AUC = Area under the Curve;
AMI = Acute Myocardial Infarction
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Table 3. Net Reclassification Improvement (Validation cohort) 
Initial model New model - cMyC (10/120) - Validation cohort
hs-cTnT No AMI (n=1089) AMI (n=219)
Rule-out Observe Rule-in Rule-out Observe Rule-in
Rule-out 249 77 0 0 1 0
Observe 190 509 32 1 66 24
Rule-in 0 7 25 0 9 118
NRI 0.081 (95% CI, 0.029-0.113) 0.068 (95% CI, 0.016-0.121)
NRI (dimensionless) 0.149 (95% CI, 0.089-0.210); p value <0.001 IDI 0.050 (95% CI, 0.029-0.070)
Thresholds Sensitivity (95% CI) NPV (95% CI) Specificity (95% CI) PPV (95% CI)
hs-cTnT 5 ng/L 99.6% (98.5-100%) 99.7% (99-100%) 29.9% (27.3-32.5%) 22.2% (19.6-24.8%)
hs-cTnT 52 ng/L 58.1% (51.6-64%) 92% (90.5-93.5%) 97.1% (96.1-98%) 80.1% (73.2-86.2%)
cMyC 10 ng/L 99.5% (98.6-100%) 99.8% (99.3-100%) 38.8% (35.8-41.7%) 24.6% (21.8-27.4%)
cMyC 120 ng/L 64.9% (58.5-71.2%) 93.1% (91.4-94.5%) 94.8% (93.5-96%) 71.5% (64.7-78%)
Initial model New model - cMyC (10/120) – Validation cohort
hs-cTnI No AMI (n=1080) AMI (n=224)
Rule-out Observe Rule-in Rule-out Observe Rule-in
Rule-out 167 32 0 0 0 0
Observe 273 526 22 1 63 19
Rule-in 0 25 35 0 16 125
NRI 0.226 (95% CI, 0.174-0.258) 0.009 (95% CI, -0.044-0.062)
NRI (dimensionless) 0.235 (95% CI, 0.174-0.296); p value <0.001 IDI 0.078 (95% CI, 0.057-0.098)
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Initial model New model - cMyC (10/120) - Validation cohort
Thresholds Sensitivity (95% CI) NPV (95% CI) Specificity (95% CI) PPV (95% CI)
hs-cTnI 2 ng/L 100% (100-100%) 100% (100-100%) 18.4% (16-20.8%) 20.3% (18-22.7%)
hs-cTnI 52 ng/L 62.9% (56.4-68.9%) 92.5% (90.9-93.9%) 94.5% (93-95.8%) 70.4% (63.6-76.5%)
cMyC 10 ng/L 99.6% (98.6-100%) 99.8% (99.3-100%) 39.4% (36.3-42.4%) 25.5% (22.9-28.5%)
cMyC 120 ng/L 64.3% (58.1-70.7%) 92.8% (91.2-94.3%) 94.7% (93.2-96%) 71.8% (65.3-77.9%)
Legend: NRI = Net Reclassification Improvement; IDI = Integrated Discrimination Improvement; CI = Confidence Interval; NPV = Negative 
Predictive Value; PPV = Positive Predictive Value; AMI = Acute Myocardial Infarction, based on the adjudicated gold-standard diagnosis
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Figure Legends
Figure 1. Structure of cardiac Myosin-binding protein C and cardiac troponins in (A) healthy 
cardiomyocytes and (B) Ischaemia-induced cardiomyocyte damage. The highlighted N-terminal 
domain C0C1 is the binding site for the previously developed monoclonal antibodies used for 
detection of the cardiac-specific isoform of cMyC – see Baker et al, 201516
Figure 2. Baseline distribution of cMyC levels at presentation to the emergency department in 
all patients based on adjudicated final diagnosis. Boxes represent interquartile ranges, whiskers 
extend to 1.5 * IQR from the hinges (y-axis capped at 1,500 ng/L, outliers represented by light 
grey bullets). 87 ng/L represents the 99th centile based on a previous study, 120 ng/L the cut-off 
threshold for diagnostic rule-in of AMI at presentation. AMI, median 237 ng/L [IQR 71, 876 
ng/L]; unstable angina, median 21 ng/L [IQR 13, 43 ng/L]; cardiac symptoms of origin other 
than coronary artery disease, median 33 ng/L [IQR 12, 96 ng/L]; non-cardiac symptoms, median 
10 ng/L [IQR 6, 19 ng/L]; symptoms of unknown origin, median 11 ng/L [IQR 7, 16 ng/L]; 
p<0.001 for all comparisons with AMI patients 
Figure 3. ROC curves for individual biomarkers: Diagnostic performance of cMyC, hs-cTnT, 
hs-cTnI and s-cTnI in the early diagnosis of acute myocardial infarction (AMI), based on 
presentation blood sample and adjudicated AMI diagnosis. Receiver operating characteristic 
(ROC) curves describing the performance of cMyC (orange line; Area under the Curve (AUC) 
0.924), hs-cTnT (light grey line; AUC 0.927), hs-cTnI (dark grey line; AUC 0.922) and s-cTnI 
(black line; AUC 0.909*); *p<0.05 
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Figure 4. Distribution of patients in different risk categories after presentation blood tests, based 
on ESC guideline 20156 for hs-cTnT and hs-cTnI, and newly developed cut-off thresholds for 
?????????????????????????-out and >120 ng/L for rule-in of myocardial infarction. 
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Supplemental Methods 
Routine clinical assessment 
All patients underwent a clinical assessment that included medical history, physical examination, 12-lead ECG, pulse 
oximetry, standard blood test, and chest radiography according to local protocols and in accordance with the guidelines 
of the European Society of Cardiology (ESC).1 Levels of cTn were measured at presentation and serially thereafter as 
long as clinically indicated. Treatment of patients was left to discretion of the attending physician.  
Adjudication of the final diagnosis  
AMI was defined and cTn levels interpreted as recommended in current guidelines.2-5 In brief, AMI was diagnosed when 
there was evidence of myocardial necrosis with a significant rise and/or fall in a clinical setting consistent with 
myocardial ischemia. Patients with AMI were further subdivided into type 1 AMI (primary coronary events) and type 2 
AMI (ischemia due to increased demand or decreased supply, for example tachyarrhythmia or hypertensive crisis).2,6 
The adjudication of final diagnoses was performed centrally in the core lab (University Hospital Basel) for all patients 
incorporating levels of hs-cTnT (see test characteristics above). More specifically, two independent cardiologists not 
directly involved in patient care reviewed all available medical records (including patient history, physical examination, 
results of laboratory testing including hs-cTnT levels, radiologic testing, ECG, echocardiography, cardiac exercise test, 
lesion severity and morphology in coronary angiography, discharge summary) pertaining to the patient from the time of 
ED presentation to 90-day follow-up. Late samples were available for adjudication of final diagnosis in all patients. In 
general, serial sampling was performed until at least 6h after presentation to the ED or onset of chest.6 In situations of 
diagnostic disagreement, cases were reviewed and adjudicated in conjunction with a third cardiologist. While discharge 
diagnoses often were correct and in agreement with the final adjudicated diagnosis, there were also cases where those 
diagnoses needed to be revised, most often because more information became available from medical testing during early 
follow-up, and more rarely, because the discharge diagnosis was not in agreement with the Universal Definition of AMI.  
The 99th percentile (14ng/L) was used as cut-off for myocardial necrosis. Absolute cTn changes were used to determine 
significant changes based on the diagnostic superiority of absolute over relative changes.7-12 Based on studies of the 
biological variation of cTn {Wu:2008bf, Vasile:2010fc} as well as on data from previous chest pain cohort studies 
{Reichlin:2011iu, Hammarsten:2012cv}, a significant absolute change was defined as a rise or fall of at least 10ng/L 
within six hours, or, in an assumption of linearity, as an absolute change of 6ng/L within three hours. Predefined 
alternative diagnoses included “unstable angina” (UA), “Cardiac symptoms of origin other than coronary artery disease” 
and “non-cardiac chest pain”.  
 3 
Clinical Care: The (hs)-cTn assays and cut-off levels used for local clinical care 
Routine clinical care comprised five different cTn assays at the different hospitals and at the different recruitment 
periods. The cTn assays used clinically in most of the participating institutions changed during the study from a 
conventional cTn assay to the hs-cTnT assay. In order to take advantage of the higher sensitivity and higher overall 
diagnostic accuracy offered by the hs-cTnT assay, patients were adjudicated using the hs-cTnT values in all patients. In 
patients in whom clinically a conventional cTn assay was used, the conventional cTn values and the hs-cTnT values were 
available for the adjudication. In patients in whom clinically the hs-cTnT assay was used, only the hs-cTnT values were 
available for the adjudication. 
The following conventional cTn assays were used: For the Roche cTnT 4th generation assay, the 10% CV level is 
0.035ug/l. The laboratories of the participating sites reported only two decimals; therefore 0.04ug/l was used as a cut-off 
for myocardial necrosis. In order to fulfil the criteria of a significant change (30% of 99th percentile or 10% CV level), a 
patient would e.g. need to have a level of <0.01ug/l at presentation and 0.04ug/l at 6h. A patient would also qualify if the 
first level is 0.02ug/l and the second 0.04ug/l. A patient would not fulfil the criteria if the first level is 0.03ug/l and the 
second is 0.04ug/l. If the first level is 0.04ug/l, the second level needs to be at least 0.06ug/l.  
For the Abbott Axsym cTnI ADV, the 10% CV level is 0.16ug/l. A patient having 0.16ug/l at presentation would meet 
the criteria for significant change if the second was ≥0.21ug/l. A patient having <0.12ug/l at presentation (limit of 
detection) would qualify if the second is >0.16ug/l.  
For the Beckmann Coulter Accu cTnI, the 10% CV level is 0.06ug/l. A patient having 0.06ug/l at presentation would 
qualify if the second is ≥0.08ug/l. A patient having 0.05 at presentation would qualify if the second is 0.07ug/l, but not 
0.06ug/l. A patient having undetectable cTnI (cTnI<0.01ug/l) at presentation would qualify if the second is ≥0.06ug/l. 
For the Siemens Dimension Vista s-cTnI, the 10% CV level is 40ng/L. The limit of detection is 15ng/L and the 99th 
percentile is 45ng/L. An absolute change of 20ng/L or more within 3-6h was considered significant. 
For Elecsys hs-cTnT measured clinically, the same change criteria were applied as for hs-cTnT measured from the study 
blood samples. 
Central adjudication: Definition of rise and/or fall in high-sensitivity cardiac troponin T (hs-cTnT)  
Absolute changes in hs-cTnT were used to determine significant changes based on the diagnostic superiority of absolute 
over relative changes.7-12 Based on studies of the biological variation of cTn 13,14 as well as on data from previous chest 
 4 
pain cohort studies 15,16, a significant absolute change was defined as a rise or fall of at least 10 ng/L within 6 hours or an 
absolute change of 6 ng/L within 3 hours. If later clinical samples (e.g., at 24, 48, or 72 hours) revealed a lower hs-cTnT 
level than that measured during the period of sampling in the ED, the later level was considered the true baseline level 
for the calculation of the change criteria. 
Measurement of high-sensitivity cardiac troponin I, high-sensitivity cardiac troponin T and sensitive cardiac 
troponin I  
After collection and subsequent centrifugation, samples were frozen at -80ºC until assayed in a blinded fashion in a 
dedicated core laboratory. The Roche hs-cTnT assay was measured on the Elecsys 2010 (Roche Diagnostics). The limit 
of blank and LoD were determined to be 3 and 5 ng/L, respectively. The 99th-percentile of a healthy reference 
population was reported at 14 ng/L with an imprecision corresponding to 10% CV at 13 ng/L.17 This study does not 
include any measurements with hs-cTnT lots that required the revision of the calibration curve.18-22 The Abbott hs-cTnI 
assay used was the final pre-commercial release version of the ARCHITECT High Sensitive STAT Troponin I assay 
(Abbott Laboratories, Abbott Park, IL, USA). Samples were thawed, mixed, and centrifuged (for 30 min at 3000 RCF 
and 4ºC for serum samples or for 10 min, twice, at 3000 RCF for plasma samples) prior to analysis and according to 
manufacturer's instructions. The hs-cTnI assay has a 99th percentile concentration of 26.2 ng/L with a corresponding 
coefficient of variation (CV) of <5% and a limit of detection (LoD) of 1.9 ng/L.23 The cTnI-ultra assay was performed 
with the use of the ADVIA Centaur immunoassay system (Siemens). Limit of detection is 6 ng/L; a 10% coefficient of 
variation was reported at 30 ng/L with the 99th percentile cut-off point of 40 ng/L.24,25 Calculation of the glomerular 
filtration rate was performed using the abbreviated Modification of Diet in Renal disease formula.26 
Measurement of cardiac myosin-binding protein C 
We have previously described the creation, biophysical selection and organ specificity of mouse monoclonal antibodies 
recognising cardiac-restricted epitopes within the N-terminus of cMyC.27 Two of these antibodies, 1A4 and 3H8, were 
used to create a sensitive sandwich immunoassay. In brief, Magnetic microparticles (MPs) for capture were prepared by 
binding 25µg of mouse monoclonal (1A4) per mg of MPs. The coated MPs were diluted in assay buffer (proprietary mix 
with custom 450mM NaCl and 0.5% Triton X-100) to 100µg/mL. Due to sample volume constraints, serum, plasma or 
analyte (recombinant C0C2 domain of cMyC)27 were diluted 2.2 fold with standard diluent and 100µL added per well of 
a 96-well assay plate. Samples or standards were then exposed to 100µL of coated MPs and agitated for 2 hours at 25°C. 
MPs were retained via a magnetic bed with unbound material removed in a single wash step. Fluorescently-labelled 
mouse monoclonal (3H8) detection antibody was diluted in assay buffer to 100ng/mL. To each well, 20µL of detection 
antibody was added and the MPs agitated for 1 hour at 25°C, retained via a magnetic bed and then washed 4 times to 
 5 
remove any unbound detection reagent. The MPs were then transferred to a new plate and all buffer was aspirated. The 
MPs were then exposed to 20µL/well of elution buffer B for 5 minutes at 25°C before transfer to a 384-well plate 
containing 10µL/well of neutralization buffer D. Fluorescent label was then detected by single molecule counting using 
the Erenna system with a dwell time of 60s per well. Three signal outputs were obtained from the Erenna System: 
Detected Events (DEs; low end signal), Event Photons (EPs; low end and higher end signal), and Total Photons (TPs; 
high end signal). 
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Supplemental Tables 
Table S1. Comparison of biomarkers in patients excluded because of uncertain final diagnosis (e.g. patients 
discharged based on negative result on conventional cTn assay, who then tested positive on high-sensitivity cTn 
assay); comparison is performed for all patients with a measured cMyC at baseline (N=60) and all patients 
including missing values (N=92) 
Biomarker N Median ng/L [IQR] 
cMyC at 0h 60 36 [24-62] 
hs-cTnI at 0h 56 11 [7-21] 
hs-cTnT at 0h 60 21 [16-28] 
 
All patients 92  
cMyC at 0h 60 36 [24-62] 
hs-cTnI at 0h 78 11 [6-19] 
hs-cTnT at 0h 92 22 [17-29] 
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Table S2. Demographics: group qualifying for primary analysis (n=1954) vs patients excluded due to missing 
cMyC values at baseline 
Demographics All patients (n = 1954) 
Excluded 
patients 
(n=875) 
p value* 
for 
comparison 
derivation vs 
validation 
Age, years 62 ± 16 59 ± 16 <0.001 
Male 1341 (69)   587 (67)    0.441 
Risk factors    
Hypertension 1247 (64)   384 (44)    <0.001 
Hyperlipidaemia 992 (51)   421 (48)    0.206 
Diabetes mellitus 348 (18) 136 (16) 0.155  
Current smoking 476 (24) 244 (28) 0.051 
History of smoking 1194 (61) 553 (63) 0.297 
History    
Coronary artery disease 710 (36) 272 (31) 0.008 
Previous myocardial infarction 474 (24) 199 (23) 0.408 
Previous revascularisation (CABG or PCI) 553 (28) 237 (27) 0.535 
Peripheral artery disease 119 (6) 52 (6) 0.947 
Previous stroke 100 (5) 53 (6) 0.352 
Vital status    
Heart rate, beats/min 79 ± 20 81 ± 21 0.234 
Systolic blood pressure, mm Hg 144 ± 24 143 ± 25 0.711 
Diastolic blood pressure, mm Hg 82 ± 15 82 ± 15 0.569 
Electrocardiographic findings    
ST-segment depression 193 (10) 75 (9) 0.313 
T-wave inversion 260 (13) 89 (10) 0.026 
No significant electrocardiographic abnormalities 1469 (75) 681 (79) 0.193 
Laboratory assessment    
Estimated glomerular filtration rate, 
ml/min/1.73m2† 84 ± 26 87 ± 25 0.008 
Presentation time    
Time since chest pain onset, hours 5 [3, 12] 4 [1, 9] <0.001 
Time since chest pain peak, hours 3 [2, 7] 2 [5, 5] <0.001 
Legend: * p values for comparison included versus excluded patient groups; data are expressed as medians [1st quartile, 
3rd quartile] or means ± standard deviation, for categorical variables as numbers (percentages); CABG = Coronary Artery 
Bypass Graft; PCI = Percutaneous Coronary Intervention; † glomerular filtration rate was estimated using the 
Modification of Diet in Renal Disease (MDRD) formula  
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Table S3. STARD checklist for studies of diagnostic accuracy 
 Section & Topic No Item Reported on page # 
     
 TITLE OR 
ABSTRACT 
1 Identification as a study of diagnostic accuracy using at 
least one measure of accuracy (such as sensitivity, 
specificity, predictive values, or AUC) 
1, 3 
 ABSTRACT 2 Structured summary of study design, methods, results, 
and conclusions (for specific guidance, see STARD for 
Abstracts) 
3-4 
 INTRODUCTION 3 Scientific and clinical background, including the intended 
use and clinical role of the index test 
5-6 
  4 Study objectives and hypotheses 5-6 
 METHODS    
 Study design 5 Whether data collection was planned before the index test 
and reference standard were performed (prospective 
study) or after (retrospective study) 
7 
 Participants 6 Eligibility criteria  7 
  7 On what basis potentially eligible participants were 
identified  
(such as symptoms, results from previous tests, inclusion 
in registry) 
7 
  8 Where and when potentially eligible participants were 
identified (setting, location and dates) 
7-8 
  9 Whether participants formed a consecutive, random or 
convenience series 
7 
 Test methods 10a Index test, in sufficient detail to allow replication 8-9 and supplement 
  10b Reference standard, in sufficient detail to allow 
replication 
8-9 and supplement 
  11 Rationale for choosing the reference standard (if 
alternatives exist) 
n/a 
  12a Definition of and rationale for test positivity cut-offs or 
result categories  
of the index test, distinguishing pre-specified from 
exploratory 
9-10 
  12b Definition of and rationale for test positivity cut-offs or 
result categories  
of the reference standard, distinguishing pre-specified 
from exploratory 
9-10 
  13a Whether clinical information and reference standard 
results were available  
to the performers/readers of the index test 
7-9 
  13b Whether clinical information and index test results were 
available  
to the assessors of the reference standard 
7-9 
 Analysis 14 Methods for estimating or comparing measures of 
diagnostic accuracy 
8-10 
  15 How indeterminate index test or reference standard 
results were handled 
8-10 
  16 How missing data on the index test and reference 
standard were handled 
9 
  17 Any analyses of variability in diagnostic accuracy, 
distinguishing pre-specified from exploratory 
9 
  18 Intended sample size and how it was determined n/a 
 RESULTS    
 Participants 19 Flow of participants, using a diagram 7 and Figures S1 + 2S 
  20 Baseline demographic and clinical characteristics of 
participants 
13, table 1 
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  21a Distribution of severity of disease in those with the target 
condition 
13, figure 2, suppl table 
3S 
  21b Distribution of alternative diagnoses in those without the 
target condition 
13, table 1 
  22 Time interval and any clinical interventions between 
index test and reference standard 
n/a 
 Test results 23 Cross tabulation of the index test results (or their 
distribution) by the results of the reference standard 
13-16, tables 2+3, 
figures 3A+3B, suppl 
tables 4S+5S 
  24 Estimates of diagnostic accuracy and their precision 
(such as 95% confidence intervals) 
14 
  25 Any adverse events from performing the index test or the 
reference standard 
14-15 
 DISCUSSION    
  26 Study limitations, including sources of potential bias, 
statistical uncertainty, and generalisability 
20 
  27 Implications for practice, including the intended use and 
clinical role of the index test 
2, 18-21 
 OTHER 
INFORMATION 
   
  28 Registration number and name of registry 4, 7 
  29 Where the full study protocol can be accessed 7 
  30 Sources of funding and other support; role of funders 22-24 
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Table S4. Demographics for derivation and validation cohorts 
Demographics All patients (n = 1954) 
Derivation 
(n = 586) 
Validation 
(n = 1368) 
p value* 
for 
comparison 
derivation vs 
validation 
Age, years 62 ± 16 62 ± 16 62 ± 16 0.777 
Male 1341 (69) 393 (67) 948 (69) 0.357 
Acute Myocardial Infarction 340 (17) 107 (18) 233 (17) 0.512 
Risk factors     
Hypertension 1247 (64) 362 (62) 885 (65) 0.239 
Hyperlipidaemia 992 (51) 290 (49) 702 (51) 0.489 
Diabetes mellitus 348 (18) 99 (17) 249 (18) 0.505 
Current smoking 476 (24) 148 (25) 328 (24) 0.602 
History of smoking 1194 (61) 372 (63) 864 (63) 0.906 
History     
Coronary artery disease 710 (36) 200 (34) 510 (37) 0.202 
Previous myocardial infarction 474 (24) 136 (23) 338 (25) 0.515 
Previous revascularisation (CABG or PCI) 553 (28) 153 (26) 400 (29) 0.176 
Peripheral artery disease 119 (6) 33 ( 6) 86 ( 6) 0.652 
Previous stroke 100 (5) 27 ( 5) 73 ( 5) 0.577 
Vital status     
Heart rate, beats/min 79 ± 20 80 (20) 79 (21) 0.895 
Systolic blood pressure, mm Hg 144 ± 24 145 ± 25 143 ± 24 0.058 
Diastolic blood pressure, mm Hg 82 ± 15 82 ± 15 82 ± 15 0.765 
Electrocardiographic findings     
ST-segment depression 193 (10) 53 (9) 140 (10) 0.475 
T-wave inversion 260 (13) 64 (11) 196 (14) 0.05 
No significant electrocardiographic abnormalities 1469 (75) 456 (80) 1013 (76) 0.075 
Laboratory assessment     
Estimated glomerular filtration rate, 
ml/min/1.73m2† 84 ± 26 84 ± 25 84 ± 26 0.441 
Presentation time     
Time since chest pain onset, hours 5 [3, 12] 5 [2, 12] 5 [3, 12] 0.804 
Time since chest pain peak, hours 3 [2, 7] 4 [2, 7] 3 [2, 7] 0.528 
Legend: * p values for comparison validation to derivation cohort; data are expressed as medians [1st quartile, 3rd 
quartile] or means ± standard deviation, for categorical variables as numbers (percentages); CABG = Coronary Artery 
Bypass Graft; PCI = Percutaneous Coronary Intervention; † glomerular filtration rate was estimated using the 
Modification of Diet in Renal Disease (MDRD) formula  
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Table S5. Blood concentrations of cMyC, hs-cTnT, hs-cTnI and s-cTnI at presentation in the five diagnostic 
categories 
Adjudicated diagnosis cMyC (ng/L) hs-cTnT (ng/L) hs-cTnI (ng/L) s-cTnI (mg/L) 
AMI 237 [71-876] 62 [28-139] 97 [21-456] 0.175 [0.039-0.722] 
Unstable angina 21 [13-43] 11 [7-17] 6 [4-12] 0.009 [0.005-0.020] 
cardiac symptoms of origin 
other than coronary artery 
disease 
33 [12-96] 15 [7-32] 10 [4-30] 0.017 [0.005-0.044] 
non-cardiac symptoms 10 [6-19] 6 [4-10] 3 [2-5] 0.005 [0.004-0.011] 
symptoms of unknown origin 11 [7-16] 6 [3-10] 3 [2-5] 0.005 [0.001-0.010] 
Legend: AMI = acute myocardial infarction; data is quoted in median ng/L [Interquartile Range] for cMyC and hs-cTn 
assays, and mg/L [IQR] for s-cTnI 
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Table S6. Blood concentrations of biomarkers above 99th centiles at presentation 
cMyC >87 ng/L      AMI            UA       non-coronary   non-cardiac  unknown   p  N  
 N=237       N=18       N=72      N=22       N=1                   
cMyC at 0h 559 [215-1228] 135 [113-207] 168 [120-329] 157 [101-222] 96 [96-96]  <0.001   350 
hs-cTnI at 0h 230 [74-725]  42 [17-74]   81 [34-227]  29 [15-43]   3 [3-3]    <0.001   327 
hs-cTnT at 0h 92 [51-182]   29 [24-43]   50 [35-88]   26 [19-47]   8 [8-8]    <0.001   337 
adjusted R2: cMyC and hs-cTnI 0.230, cMyC and hs-cTnT 0.504, hs-cTnT and hs-cTnI 0.608 
hs-cTnI >26 ng/L AMI UA non-coronary non-cardiac unknown p N 
 N=226      N=21     N=67     N=30     N=0      
cMyC ng/L at 0h 524 [208-1230] 60 [30-134] 158 [99-344] 75 [36-167] NA <0.001 344 
hs-cTnI ng/L at 0h  235 [84-739]  60 [53-98]  91 [49-229]  42 [30-65]  NA <0.001 344 
hs-cTnT ng/L at 0h  93 [54-183]   22 [14-32]   50 [35-88]  27 [15-47]  NA <0.001 332 
adjusted R2: cMyC and hs-cTnI 0.230, cMyC and hs-cTnT 0.528, hs-cTnT and hs-cTnI 0.602 
hs-cTnT >14 ng/L AMI UA non-coronary non-cardiac unknown p N 
 N=290     N=63    N=135     N=150    N=0      
cMyC ng/L at 0h 328 [97-998] 48 [24-83] 91 [46-165]  34 [19-57]  NA <0.001 638 
hs-cTnI ng/L at 0h 134 [33-557] 14 [7-38]  28 [14-87]  10 [6-19]  NA <0.001 600 
hs-cTnT ng/L at 0h 70 [36-147]  21 [17-26]  31 [20-52]  20 [16-27]  NA <0.001 638 
adjusted R2: cMyC and hs-cTnI 0.274, cMyC and hs-cTnT 0.567, hs-cTnT and hs-cTnI 0.617 
Legend: AMI = acute myocardial infarction; UA = unstable angina; data is quoted in median ng/L [Interquartile Range] 
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Table S7. Non-Cardiac sources of cMyC variation 
 AMI group (N=340) p N 
Gender - male vs female 207 [62-814] vs 361 [91-1006] 0.096 256 
Age - <65 vs ≥65 237 [62-938] vs 237 [74-826] 0.925 122 
Body Mass Index (BMI) - <30 vs ≥30 264 [72-898] vs 219 [76-616] 0.414 257 
Hypertension - absent vs present  272 [64-885] vs 230 [73-874] 0.935 71 
Hyperlipidaemia - absent vs present  321 [92-840] vs 211 [57-887] 0.140 113 
Diabetes mellitus - absent vs present  282 [75-1004] vs 182 [64-535] 0.059 245 
Current smoking - absent vs present  257 [66-894] vs 213 [78-822] 0.681 249 
History of smoking - absent vs present  219 [70-837] vs 274 [72-894] 0.701 198 
Coronary artery disease - absent vs present  308 [79-973] vs 206 [60-785] 0.135 166 
Estimated glomerular filtration rate, ml/min/1.73m2* - 
<60 vs ≥60 345 [87-953] vs 208 [60-828] 0.111 101 
 
 Non-cardiac chest pain group (N=1052)   
Gender – male vs female 10 [6-19] vs 10 [5-18] 0.108 716 
Age - <65 vs ≥65 8 [5-13] vs 18 [11-32] <0.001 701 
Body Mass Index (BMI) - <30 vs ≥30 10 [6-19] vs 11 [6-21] 0.282 815 
Hypertension – absent vs present  7 [5-12] vs 14 [9-29] <0.001 509 
Hyperlipidaemia – absent vs present 8 [5-15] vs 14 [8-28] <0.001 634 
Diabetes mellitus – absent vs present  10 [6-17] vs 16 [10-35] <0.001 916 
Current smoking – absent vs present  11 [7-21] vs 8 [5-14] <0.001 769 
History of smoking – absent vs present  10 [6-17] vs 13 [7-23] <0.001 707 
Coronary artery disease – absent vs present  9 [6-15] vs 18 [11-32] <0.001 784 
Estimated glomerular filtration rate, ml/min/1.73m2* - 
<60 vs ≥60 30 [16-53] vs 9 [6-16] <0.001 107 
Legend: MI = myocardial infarction, based on the adjudicated gold-standard diagnosis; CABG = Coronary Artery 
Bypass Graft; PCI = Percutaneous Coronary Intervention; data is quoted in median [Interquartile Range]; N = number of 
patients with the condition on the left-hand side of the demographic factors (e.g. ‘Hypertension – absent in 509 
patients’); *glomerular filtration rate was estimated using the Modification of Diet in Renal Disease (MDRD) formula 
  
  
 14 
Table S8. Multiple regression to determine influence of baseline variables on cMyC levels 
Non-cardiac chest pain group R2 B SE B βi p 
 0.077     
Constant  -32.439 11.893  0.006 
Hypertension  2.040 3.860 0.020 0.597 
Hyperlipidaemia  1.326 4.127 0.013 0.748 
Diabetes mellitus  1.139 5.047 0.007 0.822 
Current smoking  -1.914 3.978 -0.017 0.631 
History of smoking  -3.531 3.680 -0.033 0.338 
Coronary artery disease  9.658 4.552 0.083 0.034 
Creatinine on admission  0.357 0.072 0.157 0.000 
Age  0.399 0.113 0.127 0.000 
Body Mass Index (BMI)  -0.007 0.328 -0.001 0.982 
 0.075     
Constant  -34.087 7.050  0.000 
Coronary artery disease  10.680 3.662 0.093 0.004 
Creatinine on admission  0.351 0.070 0.155 0.000 
Age  0.428 0.099 0.137 0.000 
 
AMI group R2 B SE B βi p 
 0.028     
Constant  516.589 496.148  0.299 
Hypertension  -1.724 121.878 -0.001 0.989 
Hyperlipidaemia  141.837 106.276 0.082 0.183 
Diabetes mellitus  -236.237 108.644 -0.129 0.030 
Current smoking  -30.010 136.079 -0.016 0.826 
History of smoking  15.745 107.937 0.010 0.884 
Coronary artery disease  -175.913 102.811 -0.108 0.088 
Creatinine on admission  0.727 0.933 0.045 0.436 
Age  -0.459 4.339 -0.007 0.916 
Body Mass Index (BMI)  4.402 11.964 0.023 0.713 
 0.014     
Constant  
674.182 52.552  0.000 
Diabetes mellitus  
-220.143 100.580 -0.119 0.029 
Legend: AMI = Acute Myocardial Infarction; R2 = fit of the regression model; B = beta estimate; SE B = standard errors 
of beta estimate;  βi = standardized beta estimate  
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Table S9. Derivation cohort – hs-cTnT 
Initial model New model - cMyC (10/120) - Derivation cohort 
hs-cTnT  No AMI (n=465) AMI (n=103) 
 Rule-out Observe Rule-in Rule-out Observe Rule-in 
Rule-out 105 28 0 0 0 0 
Observe 95 221 8 0 41 10 
Rule-in 0 0 8 0 3 49 
NRI 0.127 (95% CI, 0.061-0.173) 0.068 (95% CI, 0.0-0.136) 
NRI (dimensionless) 0.195 (95% CI, 0.113-0.277); p value <0.001 IDI 0.065 (95% CI, 0.037-0.093) 
Thresholds Sensitivity (95% CI) NPV (95% CI) Specificity (95% CI) PPV (95% CI) 
hs-cTnT 5 ng/L 100% (100-100%) 100% (100-100%) 28.8% (24.8-33.1%) 23.8% (19.4-27.8%) 
hs-cTnT 52 ng/L 50.5% (41.3-60.4%) 89.9% (87.4-92.6%) 98.3% (97-99.3%) 86.9% (77.2-94.1%) 
cMyC 10 ng/L 100% (100-100%) 100% (100-100%) 41.3% (36.8-45.9%) 27.3% (22.9-31.9%) 
cMyC 120 ng/L 57.1% (47.5-67%) 91.1% (88.5-93.6%) 96.6% (94.8-98.1%) 78.9% (68.8-87.6%) 
Legend: NRI = Net Reclassification Improvement; IDI = Integrated Discrimination Improvement; CI = Confidence 
Interval; NPV = Negative Predictive Value; PPV = Positive Predictive Value; AMI = Acute Myocardial Infarction, based 
on the adjudicated gold-standard diagnosis 
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Table S10. Derivation cohort – hs-cTnI 
Initial model New model - cMyC (10/120) – Derivation cohort 
hs-cTnI No AMI (n=457) AMI (n=96) 
 Rule-out Observe Rule-in Rule-out Observe Rule-in 
Rule-out 61 10 2 0 0 0 
Observe 141 224 3 0 37 5 
Rule-in 1 4 11 0 6 48 
NRI 0.287 (95% CI, 0.217-0.336) -0.010 (95% CI, -0.081-0.060) 
NRI (dimensionless) 0.276 (95% CI, 0.191-0.361); p value <0.001 IDI 0.090 (95% CI, 0.062-0.119) 
Thresholds Sensitivity (95% CI) NPV (95% CI) Specificity (95% CI) PPV (95% CI) 
hs-cTnI 2 ng/L 100% (100-100%) 100% (100-100%) 15.9% (12.7-19.3%) 20% (16.3-23.8%) 
hs-cTnI 52 ng/L 55.9% (46.2-66%) 91.3% (88.8-93.7%) 96.5% (94.9-98%) 77.3% (66.7-86.4%) 
cMyC 10 ng/L 100% (100-100%) 100% (100-100%) 42.7% (38.3-47.4%) 26.9% (22.2-31.1%) 
cMyC 120 ng/L 55.3% (45.8-64.8%) 91.2% (88.5-93.6%) 96.5% (94.8-98%) 77.1% (66.7-86.1%) 
Legend: NRI = Net Reclassification Improvement; IDI = Integrated Discrimination Improvement; CI = Confidence 
Interval; NPV = Negative Predictive Value; PPV = Positive Predictive Value; AMI = Acute Myocardial Infarction, based 
on the adjudicated gold-standard diagnosis 
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Table S11. Net Reclassification Improvement – Onset of chest pain <3 hours prior to presentation 
Initial model New model - MyC (10/120) - chest pain for <3hrs 
hs-cTnT  No AMI (n=382) AMI (n=78) 
 Rule-out Observe Rule-in Rule-out Observe Rule-in 
Rule-out 99 28 0 0 1 0 
Observe 83 161 6 0 38 10 
Rule-in 0 0 5 0 1 28 
NRI 0.128 (95% CI, 0.055-0.181) 0.128 (95% CI, 0.044-0.213) 
NRI (dimensionless) 0.256 (95% CI, 0.157-0.356); p value <0.001 IDI 0.086 (95% CI, 0.052-0.119) 
Thresholds Sensitivity (95% CI) NPV (95% CI) Specificity (95% CI) PPV (95% CI) 
hs-cTnT 5 ng/L 98.8% (95.8-100%) 99.2% (97.5-100%) 33.3% (28.6-38.1%) 23.3% (19-27.9%) 
hs-cTnT 52 ng/L 37.2% (25.9-48.2%) 88.5% (85.3-91.4%) 98.7% (97.5-99.7%) 86.1% (73.3-96.9%) 
cMyC 10 ng/L 100% (100-100%) 100% (100-100%) 46.4% (41.5-51.6%) 27.5% (22.3-32.5%) 
cMyC 120 ng/L 49% (36.8-60%) 90.4% (87.4-93.2%) 97.2% (95.3-98.7%) 77.8% (65.2-89.7%) 
  
Initial model New model - MyC (10/120) - chest pain for <3hrs 
hs-cTnI  No AMI (n=381) AMI (n=79) 
 Rule-out Observe Rule-in Rule-out Observe Rule-in 
Rule-out 76 11 1 0 0 0 
Observe 109 169 4 0 39 8 
Rule-in 0 5 6 0 4 28 
NRI 0.257 (95% CI, 0.185-0.310) 0.051 (95% CI, -0.032-0.133) 
NRI (dimensionless) 0.308 (95% CI, 0.210-0.406); p value <0.001 IDI 0.101 (95% CI, 0.067-0.135) 
Thresholds Sensitivity (95% CI) NPV (95% CI) Specificity (95% CI) PPV (95% CI) 
hs-cTnI 2 ng/L 100% (100-100%) 100% (100-100%) 23.2% (19-27.1%) 21.3% (16.8-25.7%) 
hs-cTnI 52 ng/L 40.3% (29.5-51.2%) 88.7% (85.5-91.7%) 97.2% (95.5-98.7%) 74.8% (60.7-87.5%) 
cMyC 10 ng/L 100% (100-100%) 100% (100-100%) 47.1% (42.4-52.2%) 28.2% (22.9-33.3%) 
cMyC 120 ng/L 45.6% (34.7-57.3%) 89.6% (86.7-92.6%) 97.1% (95.3-98.7%) 76.6% (64.1-87.8%) 
Legend: NRI = Net Reclassification Improvement; IDI = Integrated Discrimination Improvement; CI = Confidence 
Interval; NPV = Negative Predictive Value; PPV = Positive Predictive Value; AMI = Acute Myocardial Infarction, based 
on the adjudicated gold-standard diagnosis   
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Table S12. Net Reclassification Improvement – Onset of chest pain ≥3 hours prior to presentation 
Initial model New model - MyC (10/120) - chest pain for ≥3hrs 
hs-cTnT  No AMI (n=1172) AMI (n=244) 
 Rule-out Observe Rule-in Rule-out Observe Rule-in 
Rule-out 255 77 0 0 0 0 
Observe 202 569 34 1 69 24 
Rule-in 0 7 28 0 11 139 
NRI 0.084 (95% CI, 0.034-0.114) 0.049 (95% CI, 0.0-0.098) 
NRI (dimensionless) 0.133 (95% CI, 0.076-0.190); p value <0.001 IDI 0.044 (95% CI, 0.025-0.063) 
Thresholds Sensitivity (95% CI) NPV (95% CI) Specificity (95% CI) PPV (95% CI) 
hs-cTnT 5 ng/L 100% (100-100%) 100% (100-100%) 28.4% (25.8-31%) 22.6% (20.1-25.1%) 
hs-cTnT 52 ng/L 61.4% (55.6-67.3%) 92.3% (90.9-93.9%) 97% (96-97.9%) 81.1% (75.3-86.7%) 
cMyC 10 ng/L 99.6% (98.7-100%) 99.8% (99.3-100%) 37.3% (34.8-40.3%) 24.9% (22-27.8%) 
cMyC 120 ng/L 66.9% (61-72.6%) 93.2% (91.8-94.5%) 94.7% (93.4-96%) 72.5% (66.7-78.1%) 
  
Initial model New model - MyC (10/120) - chest pain for ≥3hrs 
hs-cTnI  No AMI (n=1156) AMI (n=241) 
 Rule-out Observe Rule-in Rule-out Observe Rule-in 
Rule-out 152 31 1 0 0 0 
Observe 305 581 21 1 61 16 
Rule-in 1 24 40 0 18 145 
NRI 0.240 (95% CI, 0.190-0.270) -0.012 (95% CI, -0.061-0.036) 
NRI (dimensionless) 0.227 (95% CI, 0.170-0.285); p value <0.001 IDI 0.075 (95% CI, 0.056-0.094) 
Thresholds Sensitivity (95% CI) NPV (95% CI) Specificity (95% CI) PPV (95% CI) 
hs-cTnI 2 ng/L 100% (100-100%) 100% (100-100%) 15.9% (14-18%) 19.9% (17.7-22%) 
hs-cTnI 52 ng/L 67.5% (61.3-73.7%) 93.3% (91.9-94.7%) 94.4% (93.1-95.6%) 71.5% (65.4-77%) 
cMyC 10 ng/L 99.6% (98.6-100%) 99.8% (99.3-100%) 38.1% (35.3-41%) 25.2% (22.4-28.1%) 
cMyC 120 ng/L 66.9% (60.7-72.4%) 93.2% (91.7-94.6%) 94.6% (93.3-95.9%) 72.1% (66.2-78.3%) 
Legend: NRI = Net Reclassification Improvement; IDI = Integrated Discrimination Improvement; CI = Confidence 
Interval; NPV = Negative Predictive Value; PPV = Positive Predictive Value; AMI = Acute Myocardial Infarction, based 
on the adjudicated gold-standard diagnosis   
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Table S13. Specificity of biomarkers at presentation for adjudicated diagnosis of Acute Myocardial Infarction at 
the 99th centile 
	
 cMyC at 87 ng/L hs-cTnI at 26 ng/L hs-cTnT at 14 ng/L 
Sensitivity 69.6% (95% CI, 64.9-74.2%) 70.6% (95% CI, 65.6-75.5%) 91% (95% CI, 87.8-94.1%) 
Specificity 93% (95% CI, 91.7-94.3%) 92.3% (95% CI, 90.8-93.5%) 76.4% (95% CI, 74.3-78.6%) 
NPV 93.6% (95% CI, 92.3-94.7%) 93.8% (95% CI, 92.5-94.9%) 97.6% (95% CI, 96.7-98.4%) 
PPV 67.7% (95% CI, 62.9-72.4%) 65.4% (95% CI, 60.2-70.6%) 44.4% (95% CI, 40.7-48.2%) 
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Table S14. Prognosis – Harrell’s C and Somers’ D statistics 
n=1876 cMyC hs-cTnT p value* est.cov 
FU AMI     
Harrell's C Statistic 0.725 0.706 0.251 0.000 
Somers' D ± SD 0.450 ±0.045 0.411 ±0.048   
     
FU death     
Harrell's C Statistic 0.765 0.782 0.142 0.000 
Somers' D ± SD 0.530 ±0.034 0.564 ±0.031   
     
FU composite EP     
Harrell's C Statistic 0.745 0.749 0.667 0.000 
Somers' D ± SD 0.489 ±0.029 0.498 ±0.029   
 
n=1857 cMyC hs-cTnI p value est.cov 
FU AMI     
Harrell's C Statistic 0.724 0.714 0.577 0.000 
Somers' D ± SD 0.447 ±0.047 0.429 ±0.047   
     
FU death     
Harrell's C Statistic 0.767 0.732 0.001 0.000 
Somers' D ± SD 0.535 ±0.034 0.464 ±0.036   
     
FU composite EP     
Harrell's C Statistic 0.746 0.722 0.008 0.000 
Somers' D ± SD 0.492 ±0.029 0.443 ±0.030   
     
n=1774 cMyC s-cTnI p value est.cov 
FU AMI     
Harrell's C Statistic 0.719 0.504 <0.001 0.000 
Somers' D ± SD 0.438 ±0.047 0.007 ±0.002   
     
FU death     
Harrell's C Statistic 0.763 0.507 <0.001 0.000 
Somers' D ± SD 0.527 ±0.035 0.014 ±0.011   
     
FU composite EP     
Harrell's C Statistic 0.741 0.503 <0.001 0.000 
Somers' D ± SD 0.483 ±0.030 0.007 ±0.008   
Legend: FU = Follow-up event, AMI = Acute Myocardial Infarction (based on the adjudicated gold-standard diagnosis), 
composite EP = endpoint combining death and AMI during FU (excluding index event), Somers’ D quoted ± SD = 
Standard error of Somers’ D, est.cov = estimated covariance between two C indices; *p value for direct comparison 
between biomarkers 
Figure S1
Figure S2
Figure S3
Number at risk at 3 years
 
 
1y 2y 3y 
1st quintile 390 377 327 
2nd quintile 388 374 324 
3rd quintile 390 365 320 
4th quintile 391 356 297 
5th quintile 387 335 283 
Number at risk at 30d 
 
10d 20d 30d 
Rule-Out 457 457 456 
Observe 1194 1187 1183 
Rule-In 217 214 212 
Number at risk at 3 years
 
 
1y 2y 3y 
1st quintile 407 391 351 
2nd quintile 367 352 300 
3rd quintile 364 343 296 
4th quintile 359 329 275 
5th quintile 371 318 259 
Figure S4A-C
Number at risk at 30d
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Number at risk at 30d 
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Supplemental figure legends: 
Figure S1: Flowchart outlining recruitment numbers and exclusions from test cohort 
Figure S2: Flow of participants, depending on each biomarker used, according to ESC guideline6 for hs-cTnT and hs-
cTnI, and theoretical model for the novel biomarker cMyC; AMI = Acute Myocardial Infarction, based on the 
adjudicated gold-standard diagnosis  
Figure S3: ROC curves describing the diagnostic performance of the combination of cMyC with hs-cTnT (dark purple 
line; AUC 0.935*), hs-cTnI (light purple line; AUC 0.929) and s-cTnI (green line; AUC 0.928*); *p<0.05 
Figure S4: Cumulative incidence of death in all patients based on biomarker value at presentation: all-comers underwent 
follow-up for up to 3 years. Survival curves are plotted for hs-cTnT, hs-cTnI and cMyC based on quintiles for a three 
year follow-up, and separated in risk groups ‘Rule-Out’, ‘Observe’ and ‘Rule-In’6 at 30 day follow-up. Amongst 
quintiles, the HR for hs-cTnT at three year follow-up was 2.3 (95% CI, 0.6-9.0) in the second quintile, 7.7 (95% CI, 2.3-
25.8) in the third, 17.7 (95% CI, 5.5-57.1) in the fourth and 33.6 (95% CI, 10.6-106.3) in the fifth quintile. The HR for 
hs-cTnI was 6.6 (95% CI, 1.5-29.2), 11.3 (95% CI, 2.7-48.3), 25.1 (95% CI, 6.1-103.3) and 39.7 (95% CI, 9.7-161.8), 
respectively. The HR for cMyC was 2.6 (95% CI, 0.7-10.0), 7.8 (95% CI, 2.3-25.9), 17.2 (95% CI, 5.4-55.0) and 29.4 
(95% CI, 9.3-93.2). 
The quintiles comprise of the following tiers:  
hs-cTnT (figure S3a): [ 0.0, 4.1) [ 4.1, 7.1) [ 7.1, 12.1) [12.1, 27.5) [27.5, 1750.0] 
hs-cTnI (figure S3b): [ 0.2, 2.3) [ 2.3, 3.6) [ 3.6, 6.8) [ 6.8, 22.9) [22.9, 25351.6] 
cMyC (figure S3c): [ 1.27, 6.92) [ 6.92, 12.24) [12.24, 24.19) [24.19, 71.71) [71.71, 4369.03] 
Additional HTML-document: 
Interactive_ROC.html: This represents an interactive document allowing the reader to assess different cut-offs of the 
respective biomarkers in isolation as well as in comparison to cMyC. This can be further adjusted to match publishing 
guidelines if the journal wishes to include in the web supplement. 
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